Pelthos Therapeutics Reports Q3 Earnings with EPS Beat and Significant Revenue Growth
Pelthos Therapeutics (PTHS) reported third-quarter financial results characterized by a significant earnings beat despite missing revenue expectations. The company posted a GAAP EPS of -$2.04, which exceeded analyst estimates by $1.21. While revenue reached $15.2 million—representing a substantial 114.1% increase year-over-year—it fell short of consensus estimates by $1.7 million. The company showed improvement in its adjusted EBITDA, reporting a loss of $5.6 million for the third quarter of 2026. This is an improvement compared to the $(10.4) million loss recorded in the third quarter of 2025 and the $(5.7) million loss from the previous quarter. Despite these operational improvements, recent market sentiment has been pressured by news regarding a merger deal with Castle Creek.
Tickers: $PTHS